Construction work paused at 235 East 42nd Street, David Werner and Metro Loft’s massive office-to-resi conversion in Midtown ...

The trend in the state is consistent with an uptick in several parts of the country, including New York and California.

Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate ...

The market offers significant opportunities driven by increasing demand for personalized therapies, especially in oncology and rare diseases. Targete ...

Pfizer is making significant strides in the oncology sector, boasting a robust lineup of cancer treatments. Its oncology ...

Pfizer’s PFE second-quarter 10% revenue growth and adjusted EPS of $0.78 were ahead of consensus expectations. Management maintained full-year revenue guidance of $61 billion-$64 billion and ...

In 53% of cases, PFE stock has experienced a positive one-day return following the announcement of results.

Pfizer Inc. advanced stock charts by Barron's. View PFE historical stock data and compare to other stocks, and exchanges.

Dr. Philip Dormitzer, former global head of vaccine research and development at Pfizer, has been subpoenaed by the House Judiciary Committee as it investigates Pfizer’s alleged delay in the ...

The House Judiciary Committee subpoenaed a former Pfizer executive who allegedly claimed senior members of the company delayed the results of COVID-19 vaccine trials to influence the 2020 election.

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.